Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245489 · ClinicalTrials.gov registry record · Phase 1
Anti-platelet + Pembro for H&N Tumors
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03245489 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 20 participants.
The verdict
NCT03245489, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Interventions
- DRUG Pembrolizumab
- DRUG Clopidogrel
- DRUG acetylsalicylic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-03-06 |
| Est. Completion | 2024-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03245489
The ClinicalTrials.gov registry entry for NCT03245489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03245489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03245489 about?
NCT03245489 is a clinical study titled "Anti-platelet + Pembro for H&N Tumors". The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT03245489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-03-06. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT03245489?
The interventions under investigation include: Pembrolizumab (DRUG), Clopidogrel (DRUG), acetylsalicylic acid (DRUG).
Who is sponsoring clinical trial NCT03245489?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.